ES2200646A1 - Uso de la cardiotrofina en enfermedades hepaticas. - Google Patents

Uso de la cardiotrofina en enfermedades hepaticas.

Info

Publication number
ES2200646A1
ES2200646A1 ES200102120A ES200102120A ES2200646A1 ES 2200646 A1 ES2200646 A1 ES 2200646A1 ES 200102120 A ES200102120 A ES 200102120A ES 200102120 A ES200102120 A ES 200102120A ES 2200646 A1 ES2200646 A1 ES 2200646A1
Authority
ES
Spain
Prior art keywords
cardiotrophin
stat
proliferation
activity
hepatocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200102120A
Other languages
English (en)
Other versions
ES2200646B1 (es
Inventor
De Abajo Matilde Bustos
Valtuena Jesus Prieto
Sagastibelza Juan Jose Lasarte
Llano Elena Baixeras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion para la Investigacion Medica Aplicada
Original Assignee
Fundacion para la Investigacion Medica Aplicada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200102120A priority Critical patent/ES2200646B1/es
Application filed by Fundacion para la Investigacion Medica Aplicada filed Critical Fundacion para la Investigacion Medica Aplicada
Priority to RU2004111977/15A priority patent/RU2279289C2/ru
Priority to CA2461007A priority patent/CA2461007C/en
Priority to BR0212903-5A priority patent/BR0212903A/pt
Priority to PT02772422T priority patent/PT1437365E/pt
Priority to PCT/ES2002/000445 priority patent/WO2003027146A1/es
Priority to EP02772422A priority patent/EP1437365B1/en
Priority to CNB028185331A priority patent/CN1243020C/zh
Priority to DE60230172T priority patent/DE60230172D1/de
Priority to MXPA04002672A priority patent/MXPA04002672A/es
Priority to DK02772422T priority patent/DK1437365T3/da
Priority to AU2002337196A priority patent/AU2002337196B2/en
Priority to JP2003530732A priority patent/JP4290004B2/ja
Priority to ES02772422T priority patent/ES2316616T3/es
Priority to AT02772422T priority patent/ATE416194T1/de
Priority to SI200230788T priority patent/SI1437365T1/sl
Publication of ES2200646A1 publication Critical patent/ES2200646A1/es
Priority to US10/798,219 priority patent/US7732397B2/en
Publication of ES2200646B1 publication Critical patent/ES2200646B1/es
Application granted granted Critical
Priority to CY20091100209T priority patent/CY1109800T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Uso de la cardiotrofina en enfermedades hepáticas. La invención describe la expresión aumentada de cardiotrofina (CT-1) durante el proceso de regeneración hepática en coincidencia con la máxima proliferación de hepatocitos y también el papel de CT-1 como estimulador de la regeneración hepática. Asimismo se describe el papel hepatoprotector de CT-1 en distintos modelos de daño agudo hepático. Todo ello pone de manifiesto la importancia del uso de CT-1 en la fabricación de composiciones útiles en el tratamiento de hepatopatías. En la invención se describe esta utilización bajo diferentes formas y procedimientos, incluyendo la proteína recombinante y la utilización de las secuencias génicas que codifican para CT-1.
ES200102120A 2001-09-21 2001-09-21 Uso de la cardiotrofina en enfermedades hepaticas. Expired - Fee Related ES2200646B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
ES200102120A ES2200646B1 (es) 2001-09-21 2001-09-21 Uso de la cardiotrofina en enfermedades hepaticas.
JP2003530732A JP4290004B2 (ja) 2001-09-21 2002-09-20 肝臓疾患におけるカルジオトロフィンの使用
CA2461007A CA2461007C (en) 2001-09-21 2002-09-20 Use of cardiotrophin in liver diseases
PT02772422T PT1437365E (pt) 2001-09-21 2002-09-20 Utilização de cardiotrofina em doenças hepáticas
PCT/ES2002/000445 WO2003027146A1 (es) 2001-09-21 2002-09-20 Uso de la cardiotrofina en enfermedades hepaticas
EP02772422A EP1437365B1 (en) 2001-09-21 2002-09-20 Use of cardiotrophin in hepatic diseases
CNB028185331A CN1243020C (zh) 2001-09-21 2002-09-20 促心激素在肝病中的应用
DE60230172T DE60230172D1 (de) 2001-09-21 2002-09-20 Verwendung von cardiotrophin bei leberkrankheiten
ES02772422T ES2316616T3 (es) 2001-09-21 2002-09-20 Uso de la cardiotrofina en enfermedades hepaticas.
DK02772422T DK1437365T3 (da) 2001-09-21 2002-09-20 Anvendelse af cardiotrophin ved hepatiske sygdomme
RU2004111977/15A RU2279289C2 (ru) 2001-09-21 2002-09-20 Применение кардиотрофина при заболеваниях печени
BR0212903-5A BR0212903A (pt) 2001-09-21 2002-09-20 Uso de cardiotrofina em doenças do fìgado
MXPA04002672A MXPA04002672A (es) 2001-09-21 2002-09-20 Uso de la cardiotrofina en enfermedades hepaticas.
AT02772422T ATE416194T1 (de) 2001-09-21 2002-09-20 Verwendung von cardiotrophin bei leberkrankheiten
SI200230788T SI1437365T1 (sl) 2001-09-21 2002-09-20 Uporaba kardiotrofina pri boleznih jeter
AU2002337196A AU2002337196B2 (en) 2001-09-21 2002-09-20 Use of cardiotrophin in hepatic diseases
US10/798,219 US7732397B2 (en) 2001-09-21 2004-03-11 Use of cardiotrophin in liver diseases
CY20091100209T CY1109800T1 (el) 2001-09-21 2009-02-25 Χρηση καρδιοτροφινης σε ηπατικες ασθενειες

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200102120A ES2200646B1 (es) 2001-09-21 2001-09-21 Uso de la cardiotrofina en enfermedades hepaticas.

Publications (2)

Publication Number Publication Date
ES2200646A1 true ES2200646A1 (es) 2004-03-01
ES2200646B1 ES2200646B1 (es) 2005-05-01

Family

ID=8498979

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200102120A Expired - Fee Related ES2200646B1 (es) 2001-09-21 2001-09-21 Uso de la cardiotrofina en enfermedades hepaticas.
ES02772422T Expired - Lifetime ES2316616T3 (es) 2001-09-21 2002-09-20 Uso de la cardiotrofina en enfermedades hepaticas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02772422T Expired - Lifetime ES2316616T3 (es) 2001-09-21 2002-09-20 Uso de la cardiotrofina en enfermedades hepaticas.

Country Status (17)

Country Link
US (1) US7732397B2 (es)
EP (1) EP1437365B1 (es)
JP (1) JP4290004B2 (es)
CN (1) CN1243020C (es)
AT (1) ATE416194T1 (es)
AU (1) AU2002337196B2 (es)
BR (1) BR0212903A (es)
CA (1) CA2461007C (es)
CY (1) CY1109800T1 (es)
DE (1) DE60230172D1 (es)
DK (1) DK1437365T3 (es)
ES (2) ES2200646B1 (es)
MX (1) MXPA04002672A (es)
PT (1) PT1437365E (es)
RU (1) RU2279289C2 (es)
SI (1) SI1437365T1 (es)
WO (1) WO2003027146A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544828A (en) * 2003-06-25 2008-10-31 Ottawa Health Research Inst Use of cardiotrophin to modulate stem cell proliferation
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
WO2011148024A2 (es) * 2010-05-24 2011-12-01 Digna Biotech,S.L. Composición para la preservación fría de órganos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029237A1 (en) 1994-04-25 1995-11-02 Genentech, Inc. Cardiotrophin and uses therefor
EP1145011B1 (en) * 1999-01-21 2005-05-18 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6719969B1 (en) * 1999-08-09 2004-04-13 The Regents Of The University Of Michigan Treatment of liver disease and injury with CXC chemokines
US20020187936A1 (en) * 2001-05-17 2002-12-12 Board Of Trustees For The University Of Illinois Methods of treating liver disease and liver damage with growth hormone and foxM1B

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HONGKUI, J. et al. "In vivo effects of cardiotrophin-1". CYTOKINE, Vol. 8, nº 12, 1996, paginas 920-926, todo el documento. *
PETERS, M. et al. "A new hepatocyte stimulating factor: Cardiotrophin-1 (CT-1)". FEBS LETTERS, Vol. 372, nº 2-3, 1995, paginas 177-180, todo el documento. *
RICHARDS, C.D. et al. "Murine Cardiotrophin-1 stimulates the acute-phase response in rat hepatocytes and H35 hepatoma cells". JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, Vol. 16, nº 1, 1996, paginas 69-75, todo el documento. *
ROBLEDO, O. et al. "Hepatocyte-derived cell lines express a functional receptor of cardiotrophin-1". EUROPEAN CYTOKINE NETWORK, Vol. 8, nº 3, 1997, paginas 245-252, todo el documento. *

Also Published As

Publication number Publication date
PT1437365E (pt) 2009-03-10
EP1437365A1 (en) 2004-07-14
EP1437365B1 (en) 2008-12-03
SI1437365T1 (sl) 2009-06-30
ATE416194T1 (de) 2008-12-15
US7732397B2 (en) 2010-06-08
CA2461007A1 (en) 2003-04-03
RU2279289C2 (ru) 2006-07-10
CA2461007C (en) 2014-02-11
JP4290004B2 (ja) 2009-07-01
US20040224888A1 (en) 2004-11-11
CN1556816A (zh) 2004-12-22
DK1437365T3 (da) 2009-03-23
WO2003027146A1 (es) 2003-04-03
RU2004111977A (ru) 2005-04-10
BR0212903A (pt) 2004-09-14
CN1243020C (zh) 2006-02-22
CY1109800T1 (el) 2014-09-10
DE60230172D1 (de) 2009-01-15
ES2316616T3 (es) 2009-04-16
ES2200646B1 (es) 2005-05-01
AU2002337196B2 (en) 2008-03-13
JP2005512966A (ja) 2005-05-12
MXPA04002672A (es) 2004-11-22

Similar Documents

Publication Publication Date Title
Silva et al. Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases
Tsuruoka et al. Inhibition of in vitro angiogenesis by lymphotoxin and interferon-γ
Ma et al. Exposure to particulate matter 2.5 (PM2. 5) induced macrophage-dependent inflammation, characterized by increased Th1/Th17 cytokine secretion and cytotoxicity
Dr. Gowen et al. Preferential inhibition of cytokine‐stimulated bone resorption by recombinant interferon gamma
Taichman et al. Effects of interleukin-1 β and tumor necrosis factor-α on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro
Cui et al. Generation of effector CD8+ T cells and their conversion to memory T cells
Bishop et al. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848
DK0636025T3 (da) Forbindelser, der er egnede til behandling af allergiske og inflammatoriske sygdomme
DE50015518D1 (de) vERFAHREN ZUR VERRINGERUNG DER ANTIGENITÄT DES ADENO-ASSOZIIERTEN VIRUS STRUKTURPROTEINS
Barillé et al. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-a complex in the pathogenesis of multiple myeloma.
Beq et al. Interleukin-7 (IL-7): immune function, involvement in the pathogenesis of HIV infection and therapeutic potential
Cho et al. Acetylshikonin suppresses invasion of Porphyromonas gingivalis‑infected YD10B oral cancer cells by modulating the interleukin-8/matrix metalloproteinase axis
CN112040960B (zh) 修饰免疫细胞以增加活性
Zhu et al. Modulation of cytokines production, granzyme B and perforin in murine CIK cells by Ganoderma lucidum polysaccharides
HUP0100314A2 (hu) Hepatocita proliferációs aktivitással rendelkező fibroblaszt növekedési faktor
Yamashita et al. Expression of activin A/erythroid differentiation factor in murine bone marrow stromal cells
BR0013202A (pt) Produção de vìrus sincicial respiratório recombinante expressando moléculas moduladoras imunes
Tagawa et al. A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects
ATE524542T1 (de) Aus knochenmarksstützzellen stammende schwann'sche zellen
ES2200646A1 (es) Uso de la cardiotrofina en enfermedades hepaticas.
Lézot et al. Dlx homeobox gene family expression in osteoclasts
Lopes-Júnior et al. Emerging cytokine networks in osteosarcoma
JP2008519769A5 (es)
AU2003260452A8 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
Martin et al. Leukaemia inhibitory factor and bone cell function

Legal Events

Date Code Title Description
PC2A Transfer of patent
EC2A Search report published

Date of ref document: 20040301

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2200646B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20190521

FD2A Announcement of lapse in spain

Effective date: 20190604